DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
Daiichi Sankyo shares tumbled sharply on Friday after the Japanese pharmaceutical company announced a delay in its annual earnings release, raising concerns among investors about its oncology business and potential financial losses. The stock of Daiichi Sankyo Co., Ltd. (TYO:4568) fell nearly 10% to 2,505.5 yen, marking its lowest level since March 2022 and making it one of the worst-performing stocks in the Nikkei 225, despite the index edging up 0.3%.
The company confirmed that it has postponed its earnings announcement to May 11 from the originally scheduled date of April 27. This decision comes as Daiichi Sankyo conducts a detailed review of its oncology portfolio, including supply chain plans and its drug development pipeline. According to the company, rapidly changing market conditions have made it necessary to reassess its projections, particularly regarding potential loss provisions linked to contract manufacturers.
In addition to the earnings delay, Daiichi Sankyo also rescheduled the release of its five-year business plan to May 11, moving it forward from the previously planned May 19 date. This shift highlights the company’s effort to provide a more comprehensive update alongside its financial results.
The delay occurs during a period of strategic transformation for Daiichi Sankyo. Earlier in April, the company sold its over-the-counter drug unit, Daiichi Sankyo Healthcare, to Suntory Holdings. This move aligns with its long-term strategy to concentrate on its core prescription drug business and strengthen its oncology pipeline.
Daiichi Sankyo has been heavily investing in cancer treatments, with a strong focus on innovative therapies like Enhertu, a high-profile drug co-developed with AstraZeneca. While this focus positions the company for future growth in the oncology market, the current uncertainty surrounding supply planning and financial adjustments has weighed on investor sentiment.
As Daiichi Sankyo navigates these challenges, market participants will closely watch its upcoming earnings report and strategic updates for clearer insights into its financial outlook and growth trajectory.
